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Phosphorylation plays a central role in the dynamic regulation of the processing of the amyloid precursor protein (APP) and the
productionof amyloid- (A), one of the clinicallymost important factors that determine the onset ofAlzheimer’s disease (AD). This has
led to the hypothesis that aberrant A production associated with AD results from regulatory defects in signal transduction. However,
conflicting findings have raised a debate over the identity of the signaling pathway that controls APPmetabolism. Here, we demonstrate
that activation of the c-Jun N-terminal protein kinase (JNK) is essential formediating the apoptotic response of neurons to A. Further-
more, we discovered that the functional loss of JNK signaling in neurons significantly decreased the number of amyloid plaques present
in the brain of mice carrying familial AD-linkedmutant genes. This correlated with a reduction in A production. Biochemical analyses
indicate that the phosphorylation of APP at threonine 668 by JNK is required for-mediated cleavage of the C-terminal fragment of APP
producedby-secretase.Overall, this studyprovides genetic evidence that JNKsignaling is required for the formationof amyloidplaques
in vivo. Therefore, inhibition of increased JNK activity associated with aging or with a pathological condition constitutes a potential
strategy for the treatment of AD.
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder char-
acterized by the presence of extracellular amyloid plaques in the
brain formed by the progressive deposition of amyloid- (A).
A is a 4 kDa peptide that derives from the sequential cleavage of
the amyloid precursor protein (APP) by - and -secretases
(Mattson, 2004). Mutations in genes associated with familial
forms of AD (FAD) result in elevated production of A that
precedes disease pathology (Hardy, 1997; Bertram et al., 2010).
These findings have led to the idea that the accumulation of A is
a primary cause of AD. A neurotoxicity is mediated, at least in
part, by enhancing the levels of reactive oxygen species (ROS)
(Behl et al., 1994). Furthermore, a positive-feedback loop by
which oxidative stress produced following the interaction of A
with the receptor for advanced glycation endproducts (RAGE)
increases RAGE expression, thereby enhancingAneurotoxicity,
has been suggested (Yan et al., 1996).
Activation of the proapoptotic c-Jun N-terminal protein ki-
nase (JNK) signaling pathway constitutes one possible mecha-
nism bywhich ROS produced by the accumulation of A impairs
synaptic function and leads to neuronal loss. This is mostly dem-
onstrated by the observation that A-induced neuronal death is
significantly reduced in cortical neurons lacking JNK expression
(Morishima et al., 2001). JNK is a member of the mitogen-
activated protein kinase (MAPK) family that phosphorylates and
activates transcription factors of the AP-1 (activator protein-1)
family, including c-Jun and ATF2, in response to various stresses
(Davis, 2000). Analogous to other MAPKs, JNK is activated by
phosphorylation at threonine (Thr) and tyrosine (Tyr) residues
by two dual-specificity MAPK kinases (MKK4 and MKK7)
(Wang et al., 2007a).
Consistent with a role of JNK signaling in mediating A tox-
icity (Morishima et al., 2001), recent studies have demonstrated
the neuroprotective effect of inhibiting JNK activity in rodent AD
models (Braithwaite et al., 2010; Ramin et al., 2011). Further-
more, JNK-mediated APP phosphorylation at Thr (T) 668 has
been proposed as a mechanism to prevent APP degradation and
increase A production in a neuroglioma cell line (Colombo et
al., 2009). The importance of this finding is highlighted by evi-
dence that T668 phosphorylation is increased in humanADbrain
(Lee et al., 2003). However, the demonstration that the cyclin-
dependent kinase 5 (Cdk5) is responsible for phosphorylating
APP at T668 in naturally degenerating CAD cells, a CNS-derived
neuronal cell line used for studying neuronal cell biology and
pathology, has challenged the idea that JNK is implicated in con-
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trolling APPmetabolism under pathologi-
cal conditions (Muresan and Muresan,
2007). In contrast, this study provided ev-
idence that JNK phosphorylates APP to
control its transport in distal neurites un-
der normal conditions.
Conflicting findings regarding the role
of JNK signaling in regulating APP pro-
cessingmay be attributed to differences in
experimental conditions and emphasize
the importance of using animal models to
identify physiologically relevant regula-
tory mechanisms. Therefore, we decided
to test the effect of the loss of JNK activ-
ity in the brain of mice that overexpress
FAD-linked mutant genes to elucidate
the requirement of JNK signaling in AD
pathology.
Materials andMethods
Mice. The mouse strains were maintained in
a pathogen-free facility at the University of
Manchester. All animal procedures were per-
formed under license in accordance with the
United Kingdom Home Office Animals (Sci-
entific Procedures) Act (1986) and institu-
tional guidelines.
Genotype determination of mice and tissues.
Offspring carrying flox alleles, creERT2, APP,
and PS1 transgenes were identified by PCR on
tail and brain tissue DNA, as previously de-
scribed (Jankowsky et al., 2004; Wang et al.,
2007b).
Tissue culture. Primary cultures of cortical
neurons were prepared from the cerebral cor-
tices of 17-d-old embryos (E17) and cultured
on poly-ornithine-precoated six-well plates in
Neurobasal media containing B27 supplement, 1% penicillin/strepto-
mycin, and 1% glutamine, as previously described (Dajas-Bailador et al.,
2008). Cells carrying the creERT2 transgene were identified by PCRs on
genomic DNA extracted from the embryos. Four days after plating, 50%
of the media was replaced by fresh Neurobasal media containing B27
supplement minus AO, 1% penicillin/streptomycin, and 1% glutamine.
Seven days after plating, neurons were incubated in 4-hydroxytamoxifen
(4-OHT) (0.1M) diluted in 95% ethanol to induce gene deletion. Three
days later, neurons were treated with A42 (200 nM; American Peptide).
A42 solubilized in DMSO was diluted in physiological buffer before
being added onto the cells. Where indicated, the cells were pretreated for
30 min with zVAD (10 M; R&D Systems) orN-acetylcysteine (NAC) (1
mM; Sigma-Aldrich), or for 1 h with a neutralizing anti-RAGE antibody
(50g/ml; R&DSystems). In Figure 5, neuronswere used 7 d (Fig. 5B,C)
and in Figure 6 neurons were used 11 d (Fig. 6B) after the addition of
4-OHT.
Preparation of cell lysates and immunoblot analysis. Proteins were ex-
tracted from cells in Triton lysis buffer (Wang et al., 2007b). Twenty to 50
g proteins were subjected to immunoblot analysis following SDS-
PAGE with antibodies against c-Jun (9165), JNK1/2 (Santa Cruz; sc-
571), MKK4 (3346), MKK7 (4172), act caspase 3 (9664), APP (Covance;
SIG-39152-200), P-T668-APP (BioSource International; 443364), RAGE
(Santa Cruz; sc-8230), or amino acids 1–17 of human A (6E10; Sigma-
Aldrich) to detect CTF. Antibodies were purchased fromCell Signaling
Technology unless indicated otherwise. Immune complexes were de-
tected by enhanced chemiluminescence with anti-goat, anti-rabbit, or
anti-mouse IgG coupled to horseradish peroxidase as the secondary
antibody.
Protein kinase assay.Endogenous JNKactivitywasmeasured in cell lysates
in the presence of [-32P]ATP following precipitation with glutathione
S-transferase (GST)-c-Jun (Wang et al., 2007b). The radioactivity incorpo-
rated into the recombinant protein was quantitated after SDS-PAGE by
PhosphorImager analysis.
Immunofluorescence. Neurons were fixed in 4% paraformaldehyde
(PFA) before being incubated with a specific antibody to MAP2 (Sigma-
Aldrich; 4542) or to RAGE (Santa Cruz; sc-8230). Immune complexes
were detected with secondary antibody conjugated to fluorescein or
Texas Red (Jackson ImmunoResearch). Nuclei were stained with DAPI
(5g/ml). Fluorescence images were viewedwith anOlympus wide-field
microscope.
Death assays. Cell survival was quantified by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Caspase activity
was measured by spectrofluorometer using the DEVD-AMC caspase
3-specific fluorogenic substrate (Alexis Biochemicals).
ELISA. Intracellular concentration of A42 wasmeasured using a spe-
cific sandwich-type ELISA (human A42 kit; Invitrogen; KHB3441; or
mouse/rat A42 kit; IBL International; 27721) according to the manu-
facturer’s instruction.
Histological and immunohistochemical analyses. Mice were anesthetized
andperfusedwith0.9%saline, followedby4%PFA.The30mcryosections
of brain were blocked in PBS containing 10% goat serum and 0.1% Triton
X-100 for 1 h at room temperature before being incubated overnight at 4°C
with primary antibodies to MKK4 (1:100; BD Biosciences Pharmingen),
MKK7 (1:100; Cell Signaling), or A42 (1:500; Alpha Diagnostic). The fol-
lowingday, the slideswere rinsed inPBSand incubatedat roomtemperature
for 1 h with secondary biotinylated anti-rabbit antibody. The slides were
processed using the ABC detection kit (Vector Laboratories). The presence
of the antigens was revealed using the DAB (diaminobenzidine) (brown)
peroxidase substrate kit (Vector Laboratories).
Electron microscopy. Brains were fixed with 2.5% PFA and 0.1% glu-
taraldehyde in phosphate buffer, and then dissected and small blocks of
Figure 1. The loss of MKK4 andMKK7 protects neurons against A42-induced apoptosis. Cortical neurons displaying homozy-
gous flmutation for themkk4 and/ormkk7 alleles and expressing () or not () CreER T2 were incubated for 72 h with 0.1M
4-OHT before being treatedwith A42 (200 nM) for the indicated times.Where indicated, the cells were pretreatedwith zVAD (10
M). A, Protein lysates were analyzed by immunoblot with antibodies against MKK4, MKK7, and JNK. B, E, Immunofluorescence
was performed with a specific antibody to MAP2. The immune complex was detected with a secondary antibody conjugated to
fluorescein (green). DNAwas stained with DAPI (blue). Scale bar, 10m. C, Caspase 3 activity wasmeasured by caspase assay.D,
Cell survival was measured by MTT assay. The data correspond to the mean SE (N 3).
16970 • J. Neurosci., November 23, 2011 • 31(47):16969–16976 Mazzitelli et al. • Role of JNK Signaling in Alzheimer’s Disease
the cerebral cortex, hippocampus, and entorhinal cortex were postfixed
with 1% osmium tetraoxide, dehydrated in methanol, and embedded in
Epon. Semithin sections were stained with toluidine blue, and selected
ultrathin sections, with uranyl acetate and lead citrate.
Results
The deletion ofmkk4 andmkk7 protects cortical neurons
from A-induced apoptosis
Mice lackingmkk4 ormkk7die before birth (Wang et al., 2007a). To
circumvent this early lethality and thereby permit the study of the
physiological function of JNK signaling in AD pathology, we devel-
oped novel mouse models in which specific
exons of the mkk4 and mkk7 genes were
flanked by LoxP sites [referred to as the flox
( fl) allele] (Wang et al., 2007b; A. Hu¨bner
and R. J. Davis, unpublished observation).
These sites, which do not interfere with the
normal expression of the genes, constitute a
binding domain for theDNA recombinase
Cre. Homozygous mkk4fl and/or mkk7fl
mice were mated with a transgenic line
expressing Cre fused to amutated form of
the ligand binding domain of the estrogen
receptor (ERT2) (Hayashi andMcMahon,
2002). The ERT2 moiety ensures the cyto-
plasmic sequestration of Cre. Cortical
neurons were prepared from the embryos
and cultured for 7 d before being incu-
bated with 4-OHT to trigger the nuclear
translocation of Cre where it specifically
recombines the fl alleles.
Immunoblot analysis confirmed that
the inactivation of the mkk4 and mkk7
genes only occurred in homozygous flox
neurons carrying the creERT2 transgene
(Fig. 1A). The loss of MKK4 and/or
MKK7 in matured neurons did not cause
any obvious change in cell morphology
(Fig. 1B,E). In subsequent experiments,
cortical neurons expressing or not Cre
and treatedwith 4-OHTwill be referred to
as (/) and (/) cells, respectively.
To determine the functional conse-
quence of the loss ofMKK4 and/orMKK7
expression, the viability of mkk4/7/,
mkk4/, mkk7/, and mkk4/7/
neurons treatedwith A42was examined.
Bright-field microscopy indicated that
mkk4/7/ neurons underwent extensive
cell death after A42 stimulation. The loss
of axon integrity, as demonstrated by the
disappearance of MAP2 staining, corre-
latedwith the detection of fragmented nu-
clei characteristic of apoptotic cells (Fig.
1B). Consistently, caspase 3 activity was
increased in neurons treated with A42
(Fig. 1C). A42-induced neuronal death
was prevented by incubating the cells with
zVAD, a well characterized caspase inhib-
itor (Fig. 1D). Similarly, A42 induced
the apoptotic death of mkk4/ and
mkk7/ neurons (Fig. 1E). In contrast,
mkk4/7/neurons remained viable (Fig.
1D,E) and did not display increased
caspase 3 activity (Fig. 1C) following A42 stimulation.
Consistent with the requirement of JNK to mediate A-
induced apoptosis (Morishima et al., 2001), A42 treatment in-
creased JNK activity in mkk4/7/ neurons with a maximum at
1 h (Fig. 2A). This was prevented following the loss ofMKK4 and
MKK7 (Fig. 2A) and significantly blocked in neurons pretreated
with the antioxidant NAC (Fig. 2B). Impaired JNK activity in
mkk4/7/ neurons correlated with low level of c-Jun expression
under both basal and stimulated conditions, supporting the evi-
dence that JNK increases the transcriptional activity of c-Jun and
Figure2. MKK4andMKK7are required forA-induced JNKactivation. Cortical neuronswere incubatedwithA42 (200nM) for
the indicated times 3 d after 4-OHT treatment to induce gene deletion.Where indicated, the cellswere pretreatedwithNAC (1mM)
or incubated in presence of a neutralizing RAGE antibody (RAGE-AB) (50 g/ml) before stimulation. A, B, E, Endogenous JNK
activity was measured by protein kinase assay. Radioactivity incorporated in the GST-c-Jun substrate was quantified by Phospho-
rImager. Values are expressedas fold of untreatedmkk4/7/ sample. Thedata correspond to themeanSE (N3) (A,B) or
SD (N 2) (E). C, Protein lysates were analyzed by immunoblot with antibodies against MKK4, MKK7, JNK1/2, c-Jun, and active
(act) caspase 3. The data are representative of three independent experiments. D, Immunofluorescence was performed with a
specific antibody to RAGE. The immune complex was detectedwith a secondary antibody conjugated to Texas Red (red). DNAwas
stained with DAPI (blue). Scale bar, 10 m. F, Caspase 3 activity was measured by caspase assay. The data correspond to the
mean SE (N 3).
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the ability of c-Jun to control its own promoter (Davis, 2000)
(Fig. 2C). Furthermore, immunoblot analysis confirmed the pro-
teolytic cleavage of caspase 3 in mkk4/7/, but not in mkk4/
7/, neurons stimulatedwithA42 (Fig. 2C). In addition,mkk4
and mkk7 gene deletion prevented A42-mediated increased
RAGE expression (Fig. 2D). The functional importance of this
finding is demonstrated by the ability of a neutralizing RAGE
antibody to block JNK activation (Fig. 2E) and increased caspase
3 activity (Fig. 2F) inmkk4/7/ neurons incubated with A42.
Overall, these studies provide genetic evidence that MKK4
andMKK7 are both required tomediate the apoptotic response
of neurons by activating JNK following A–RAGE interaction
and the production of ROS.
Inactivation of MKK4 andMKK7 in the adult forebrain
To determine the physiological significance of the loss of active JNK
inADpathology,we created amousemodel inwhich the expression
ofMKK4 andMKK7 could be specifically abolished in neurons in
the adult forebrain. This was achieved by crossing the mkk4/7fl/fl
mice with a transgenic line expressing CreERT2 under the con-
trol of theCa2/calmodulin-dependentproteinkinase II (CaMKII)
gene promoter (Erdmann et al., 2007). One-month-old mkk4/7fl/fl
littermates carrying or not the CaMKII-creERT2 transgene were
injected intraperitoneally every day for 5 d with a nontoxic amount
of tamoxifen (200 g) to induce Cre activation and the neuronal
specific deletion of the fl alleles.
Immunostaining of brain sectionswith antibodies toMKK4 and
MKK7 showed thatMKK4was highly expressed in the cerebral cor-
tex,whileMKK7wasmostly detected in theCA2andCA3 regionsof
the hippocampus (Fig. 3A). The inactivation of themkk4 andmkk7
genes only occurred in the brain of mkk4/7fl/fl mice expressing Cre
and injected with tamoxifen (Fig. 3A). This was confirmed by im-
munoblot analysis of brain extracts (Fig. 3B). Similar expression
of MKK4 and MKK7 in the cerebellum of mkk4/7fl/fl and
(CaMKII-creERT2)mkk4/7fl/fl mice injected with tamoxifen dem-
onstrated the selective ablation of the proteins in specific areas of the
brain (Fig. 3A). JNK activity was decreased by80% following the
deletion of themkk4 andmkk7 genes (Fig. 3C). Consistent with our
previous results in cell cultures (Fig. 2), this resulted in impaired
c-Jun expression (Fig. 3B). In subsequent experiments, mkk4/7fl/fl
and (CaMKII-creERT2)mkk4/7fl/flmice injected with tamoxifen will
be referred to asmkk4/7wt andmkk4/7br animals, respectively.
The loss of MKK4 andMKK7 prevents amyloid plaque
formation
To establish the requirement of JNK signaling in the onset and in
the progression of AD, we examined the effect of the loss of
MKK4 and MKK7 in the brain of mice that overexpress APP
carrying the Swedishmutation (APPswe) andpresenilin 1 lacking
exon 9 (PS1dE9) (Jankowsky et al., 2004). APPswe is a better
substrate for -secretase than -secretase (Citron et al., 1992),
while PS1dE9 confers -secretase a constitutive activity. The de-
letion of exon 9 also results in a serine-to-cysteine substitution
that alters the specificity of -secretase to favor the production of
A42 relative to the less pathogenic A40 (Perez-Tur et al., 1995).
As expected, expressionof theAPPswePS1dE9 transgene inmkk4/7wt
mice resulted in amyloid deposition as soon as 3months of agewith
a progressive increase in plaque number at 5 months (Fig. 4A,B).
The amount of A42 produced in the brain increasedwith a similar
kinetics (Fig. 4C). Electronmicroscopy confirmed the presence of
a large number of clustered dystrophic neurites filled with
altered mitochondria and residual bodies around amyloid de-
posits characteristic of AD pathology (Fig. 4D).
In contrast, the number of plaques was greatly reduced in the
absence of MKK4 and MKK7 (Fig. 4A,B). In fact, plaques that
did develop in the brain of the mkk4/7br mice carrying the
APPswe/PS1dE9 transgene were found in areas positive for
MKK4 and MKK7 expression and JNK phosphorylation. This
was expected since the deletion of fl genes following tamoxifen-
induced Cre does not occur with 100% efficiency. Consistent
with a reduction in A deposition, the level of A42 was signifi-
cantly decreased following the loss of MKK4 and MKK7 (Fig.
4C). Furthermore, MKK4/7-deficient brains displayed a marked
decrease of the number of dystrophic neurite clusters and only a
few isolated neurites with residual bodies (Fig. 4D). Together,
these results demonstrate that active JNK is required for the for-
mation of amyloid plaques in vivo.
The loss of MKK4 andMKK7 prevents the phosphorylation of
APP at T668
To understand the mechanism by which JNK signaling increases
A42 production, we investigated the effect of the loss of MKK4
and MKK7 expression on APP phosphorylation at T668, a site
known to be phosphorylated by JNK (Standen et al., 2001) and
implicated in the amyloidogenic cleavage of APP (Lee et al.,
2003). In addition, phosphorylation of APP at T668 has been
shown to be increased in human AD brain (Lee et al., 2003).
Consistent with our previous data (Figs. 2A,D, 3C), the loss of
MKK4 and MKK7 in the brain of mice expressing the APPswe/
PS1dE9 transgene caused a reduction in RAGE expression and a
Figure 3. InactivationofMKK4andMKK7 in theadult forebrain.One-month-oldmkk4/7fl/flmice
carrying () or not () the CaMKIIcreERT2 transgene were injected with tamoxifen to induce Cre-
mediated recombinationof the fl alleles.A, Onemonth later, brain sectionswere analyzedby immu-
nohistochemistry using antibodies againstMKK4 orMKK7. Scale bar, 10m.HC, Hippocampus; DG,
dentategyrus.B, Protein lysateswereanalyzedby immunoblotwith specific antibodies. Thedataare
representativeoftwoindependentexperiments.C,EndogenousJNKactivitywasmeasuredbyprotein
kinase assay. Radioactivity incorporated in the GST-c-Jun substrate was quantified by Phospho-
rImager. Values are expressed as fold ofmaximum. The data correspond to themean SD (N 2
animals).
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significant decrease in JNK activity (Fig. 5Ai). This prevented the
phosphorylation of APP at T668 (Fig. 5Aii). The low level of
phospho (P)-T668-APP correlated with the accumulation of the
full-length (FL) protein as well as a C-terminal fragment (CTF)
produced after the cleavage of APP by  or  secretases (Fig.
5Aii). Further analyses using an antibody raised against amino
acids 1–17 of human A (6E10) confirmed that mkk4 and mkk7
gene deletion increased CTF (Fig. 5Aii).
The effect ofmkk4 andmkk7 gene deletion on APP processing
was tested in cortical neurons expressing the APPswe/PS1dE9
transgene, after 14 d in culture. Consistent with our in vivo data,
the loss of MKK4 and MKK7 following Cre activation prevented
APP phosphorylation at T668, causing an accumulation of APP
and CTF (Fig. 5B). A similar phenotypic abnormality has been
observed in cortical neurons defective in PS1 or expressing loss-
of-function variants (Naruse et al., 1998). Therefore, we hypoth-
esized that mkk4 and mkk7 gene deletion increased APP level by
preventing -mediated cleavage of CTF. To test this hypothesis,
we examined the effect of DAPT, a known inhibitor of
-secretase. The results show that incubation of mkk4/7/
neurons with DAPT increased APP and CTF levels (Fig. 5Ci), as
well as cell survival (Fig. 5Cii), to a similar extent as that associ-
ated with the loss of MKK4 and MKK7. Consistent with the ob-
servation that neurons lacking MKK4 and MKK7 are less
sensitive to the expression of the APPswe/
PS1dE9 transgene thanwild-type cells, the
level of A42 was significantly lower in
mkk4/7/ than in mkk4/7/ neurons
(Fig. 5Ciii). In addition, we found that the
brain of 5-month-old mkk4/7br mice and
mkk4/7/ neurons cultured for 18 d dis-
played higher levels of APP and CTF com-
pared with wild-type (wt or/) samples
(Fig. 6Ai,Bi). Consistently, the loss of
MKK4andMKK7prevented increasedpro-
duction of A42 in aging brains and neu-
rons (Fig. 6Aii,Bii).
Together, these results provide strong
evidence that increased JNK activity
downstream of MKK4 and MKK7 is re-
quired for the amyloidogenic cleavage of
mutant, but also endogenous, APP and
A42 production.
Discussion
In this study, we demonstrated that the
loss of active JNK associated with the ab-
sence of both MKK4 and MKK7 protects
neurons against A-induced toxicity.
Furthermore, we discovered that JNK sig-
naling is required for amyloid plaque for-
mation in vivo. Together, these results
provide the first genetic demonstration
that activation of JNK triggers the cascade
of event that leads to AD pathology.
Phosphorylation plays a central role in
the dynamic regulation of APP processing
(Gandy and Greengard, 1994). This has
led to the hypothesis that aberrant A
production associated with AD results
from regulatory defects in signal trans-
duction. Our results support this idea by
providing a genetic link between amyloid
plaque formation and increased JNK ac-
tivity in neurons via the amplification of a positive-feedback loop
associated with the phosphorylation of APP at T668 (Fig. 7).
However, a previous study showed that, while JNK phosphory-
lates APP to control its transport in distal neurites under normal
conditions, Cdk5 is responsible for phosphorylating APP in nat-
urally degenerating CAD cells overexpressing or not APP (Mure-
san and Muresan, 2007). Furthermore, the role of T668
phosphorylation in promoting the amyloidogenic cleavage of
APP (Lee et al., 2003; Vingtdeux et al., 2005) has been disputed by
evidence that a knock-in mouse model in which T668 was re-
placed by an alanine residue displayed normal level of A (Sano
et al., 2006). Similarly, there is an ongoing debate over the role of
phospho-T668 in regulating APP metabolism as a consequence
of modulating its ability to interact with its binding partners. For
example, Pin1 is a peptidyl-prolyl isomerase that binds the phos-
phorylated T668 motif of APP, leading to increased A produc-
tion (Akiyama et al., 2005). However, a role of Pin1 in promoting
the nonamyloidogenic processing of APP has also been described
previously (Pastorino et al., 2006). In addition, one study sug-
gests that the interaction of Fe65 with the nonphosphorylated
form of APP stabilizes APP and inhibits A production (Ando et
al., 2001), while others have found that overexpression of Fe65
promotes the production of A (Taru and Suzuki, 2009).
Figure 4. The loss of MKK4 and MKK7 prevents the formation of amyloid plaques. A breeding program was set up to create a
mousemodel harboring homozygousmkk4fl andmkkk7fl alleles together with a transgene encoding APPswe and PS1dE9, with or
withoutCaMKII-creERT2. Littermateswere injected1monthafter birthwith tamoxifen, toproduceanimals lackingMKK4andMKK7
expression in the brain (mkk4/7br) and suitable controls (mkk4/7wt). A, The brains of 5-month-old mice were analyzed by
immunohistochemistry using an antibody toA42. Scale bars: for 5, 200m;40, 20m.B, The number (nb) of plaqueswas
counted in serial coronal brain sections at 3 and 5 months (M) after birth. C, The amount of A42 was measured by ELISA
(Invitrogen). The data correspond to themean SE (N 3 animals).D, Brain sectionswere analyzed by EM. The images are from
three distinct animals per genotype (i–iii,mkk4/7wt; iv–vi,mkk4/7br). Dystrophic neurites filled with alteredmitochondria and
residual bodies are clustered around amyloid deposits in mkk4/7wt mice (asterisks), whereas rare isolated dystrophic neurites
(arrows) are detected inmkk4/7br animals. Scale bars: i–iv, 2m; v, 1m; vi, 1.5m.
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Overall, these discrepancies may be attributed to differences
in experimental conditions (wild-type vs mutant APP; endoge-
nous vs ectopic expression; neurons in culture vs animal model).
For example, T668 phosphorylation prevents -mediated cleav-
age of wild-type APP (Feyt et al., 2007), while APPswe mutant
requires to be phosphorylated at T668 before being cleaved by
-secretase (Vingtdeux et al., 2005). In contrast, the Swedishmu-
tation that enhances the affinity of APP for -secretase may by-
pass the requirement of T668 phosphorylation, which has been
proposed to facilitate the cleavage of APP by -secretase in pri-
mary cortical neurons (Lee et al., 2003). Consequently, the func-
tional disruption of JNK signaling may affect -mediated
cleavage of wild-type APP, but not APPswe mutant. This is con-
sistent with the detection of CTF in the brain of APPswe/
PS1dE9mkk4/7br mice. Together, these apparent conflicting
findings support the hypothesis that APPmetabolism is regulated
by distinct signalingmechanisms during normal aging and in AD
condition in which mutant or wild-type forms of APP are often
expressed above physiological levels.
Therefore, although we show that JNK signaling is implicated
in the processing of endogenous APP, it will be important to
determine the requirement ofMKK4 andMKK7 in regulating the
cleavage of overexpressed wild-type APP. This will help to clarify
the specific requirement of T668 phosphorylation in controlling
 cleavage of APP. Together, this information will enable us to
predict (1) the usefulness of JNK inhibitors to treat late-onset AD
patients that do not display the Swedish mutation and (2) take
Figure5. MKK4 andMKK7 are required for APPphosphorylation at T668.A,mkk4/7fl/fl littermates carrying theADdisease geneswith orwithout CaMKII-creERT2were injected 1month after birth
with tamoxifen toproduce3- and5-month (M)-old animals lackingMKK4andMKK7expression in thebrain (mkk4/7br) and suitable controls (mkk4/7wt). i, Endogenous JNKactivity inbrain extracts
wasmeasured by protein kinase assay. Radioactivity incorporated in the GST-c-Jun substratewas quantified by PhosphorImager. The autoradiography represents two distinct animals per genotype
per time point. The data correspond to the mean SE (N 4 animals). ii, Protein lysates were analyzed by immunoblot with specific antibodies. The data represent two distinct animals per
genotype per time point. B, C, Cortical neurons were obtained frommkk4/7fl/flmice carrying the APPswe/PS1dE9 transgene with () or without () CaMKII-creERT2 and treated with 4-OHT after
7 DIV to producemkk4/7/ neurons and suitable controls (mkk4/7/). Neurons were used 7 d after the addition of 4-OHT. Where indicated, the cells were treated for 2.5 h with DAPT (1M;
Sigma-Aldrich)beforebeingharvested. Cell lysateswereanalyzedby immunoblotusing specific antibodies (B,Ci). Thedataare representativeof twoexperiments. Cell survivalwasmeasuredbyMTT
assay (ii). The amount of A42 in cell lysates was measured by ELISA (Invitrogen) (iii). The data correspond to the mean SD (N 2).
Figure 6. The amyloidogenic cleavage of endogenous APP requires JNK signaling. A,
Brains were obtained from 3- and 5-month (M)-old mkk4/7br mice and control (mkk4/
7wt) littermate. B, Cortical neurons lacking MKK4 and MKK7 (mkk4/7/) and suitable
controls (mkk4/7/) weremaintained in culture for 14 or 18 d. Lysates were analyzed by
immunoblot using an antibody against APP (i). The amount of A42 was measured by
ELISA (IBL International) (ii). The data correspond to the mean SD (N 2).
16974 • J. Neurosci., November 23, 2011 • 31(47):16969–16976 Mazzitelli et al. • Role of JNK Signaling in Alzheimer’s Disease
into account the side effects of therapeutic intervention based on
inhibiting JNK activity by considering the physiological role of
APP phosphorylation at T668 in neurite extension, a process
known to be dependent on the JIP-3/JNK pathway (Muresan and
Muresan, 2005). Another key question will be to examine the
physiological role of JNK signaling in mediating amyloid toxicity
in vivo. These issues still need to be addressed before the thera-
peutic implication of inhibiting JNK activity for treating human
AD becomes clear.
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